Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?

Eur J Clin Pharmacol. 2022 Oct;78(10):1703-1704. doi: 10.1007/s00228-022-03377-0. Epub 2022 Aug 25.

Authors

Lixin Du¹, Zhigang Li¹, Peng Lan¹, Huayu Huang¹, Wende Cheng², Jun Xia³

Affiliations

¹ Department of Medical Imaging, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.
² Department of Pathology, Shenzhen Longhua District Central Hospital, Shenzhen, 518110, China.
³ Department of Radiology, Shenzhen Second People's Hospital, Shenzhen, 518035, China. [email protected].

PMID: 36008491
DOI: 10.1007/s00228-022-03377-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases*
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Myocardial Infarction* / drug therapy
Myocardial Infarction* / prevention & control
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Stroke* / prevention & control

Substances

Hypoglycemic Agents
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors

Grants and funding

JCYJ20210324142404012/Shenzhen Fundamental Research Program (Natural Science Foundations), General Programe for Fundamental Research